Delirium (sometimes called ‘acute confusional state’) is a common clinical syndrome characterised by:

It has an acute onset and fluctuating course. Patients’ behaviour can often change dramatically over minutes to hours. Delirium may develop at any point in the patients ICU stay and continue into the ward environment. It has been shown to be a contributor to increased morbidity and mortality in the ICU patient.

Assessment of ICU patients for delirium
ICU patients should be monitored using validated delirium assessment scoring systems. Patients with delirium have been shown to have longer hospital stays and worse outcomes. Research suggests that delirium may be associated with cognitive impairment that persists months to even years after discharge from ICU.

Scoring systems and tools available
There are a number of validated delirium screening tools for use with critically ill patients. These scoring systems can be used to help diagnose delirium in ICU patients, and include:

CAM-ICU - Confusion Assessment Method for the ICU

ICDSC -Intensive Care Delirium Screening Checklist

DDS - The Delirium Detection Score (Otter et al, 2005)

The CAM-ICU is easily reproducible and has been demonstrated to increase the likelihood of the assessment being carried out by ICU staff. Routine daily screening of ICU patients is recommended (NICE, 2010 or

Classification of delirium
Delirium can be categorized into three main subtypes, according to the patient’s psychomotor behaviour:

The hyperactive type is often well recognized due to the overt behaviour displayed by the patient. The hypoactive type is less well recognized and often misdiagnosed as depression.

Causes of delirium?

Patients most likely to develop delirium in the ICU

Management of delirium
First rule out any of the above causes and remove any potential organic drivers. Unless your patient or others are at an imminent risk of harm it is advisable to treat using non-pharmacological methods in the first instance. Pharmacological agents include the use of antipsychotics/neuroleptic agents (ie. haloperidol, risperidol, quetiapine, and olanzapine). The dose and route required is dependent on the patients’ level of disturbance and co-morbidities and is titrated according to the desired therapeutic effect. Patients receiving antipsychotics/neuroleptic agents should be closely monitored for adverse side effects such as QT prolongation, arrhythmias and extrapyramidal symptoms.Benzodiazepines should be avoided although short acting benzodiazepines may beuseful in managing patients who have delirium associated with benzodiazepines or alcohol withdrawal. For more guidance (UKCPA, 2006).

North West London Critical Care Network,     Network Office,     15 Marylebone Road,     London,     NW1 5JD

+ 44 (0)203 350 4124

About Us

Subscribe to our RSS feed